Cellinta is a technology company.
Cellinta has raised $5.0M across 1 funding round.
Cellinta has raised $5.0M in total across 1 funding round.
Cellinta is a biotechnology company developing highly selective gene therapies targeting cancer stem cells to address aggressive cancers with high unmet needs.[1][2] Founded in 2019 as a portfolio company of SV Health Investors in partnership with Cancer Research UK and the University of Edinburgh, it leverages stem cell biology, synthetic biology, and cancer genomics to deliver therapeutic combinations via viral vectors, bypassing limitations of traditional single-gene or pathway-targeted treatments.[1][2] Led by CEO Dr. Soraya Bekkali, with Prof. Steven Pollard as senior scientific advisor, Cellinta serves oncology patients by advancing first-in-class therapies from academic discoveries into clinical candidates, supported by a recent collaborative research and option-to-license agreement with the University of Edinburgh.[1][2]
Cellinta emerged in 2019 from a strategic partnership between SV Health Investors, Cancer Research UK, and the University of Edinburgh's Centre for Regenerative Medicine, commercializing cancer stem cell research led by Prof. Steven Pollard, Professor of Stem Cell & Cancer Biology.[1][2][3] Pollard, the scientific founder and senior advisor, identified master regulators of cell identity to enable selective therapy delivery to cancer stem cells, building on advancements in viral vectors as a scalable gene therapy platform.[1] The company launched with investment from SV Health Investors and Cancer Research UK, facilitated by Edinburgh Innovations, and quickly appointed Dr. Soraya Bekkali—a gene therapy expert with over 20 years in drug development—as CEO, alongside Mike Ross of SV Health Investors as Chairman.[1][2] Early traction included securing intellectual property options from Pollard's lab, positioning Cellinta to rapidly translate research into treatments.[1][2]
Cellinta rides the gene therapy boom, fueled by viral vector maturation and successes in oncology, enabling precise delivery to hard-to-treat cancer stem cells that drive tumor recurrence and resistance.[1] Its timing aligns with surging demand for next-generation biologics amid limitations of small-molecule drugs, amplified by partnerships translating public-funded research (e.g., Cancer Research UK) into spinouts via investors like SV Health.[1][2][3] Market forces favoring it include rising biotech funding for precision oncology and regulatory nods for gene therapies, positioning Cellinta to influence the ecosystem by pioneering stem cell-selective treatments and bridging academia-industry gaps in the UK biotech hub of Edinburgh BioQuarter.[2]
Cellinta is poised to advance its lead programs into clinical trials, leveraging its IP option from the University of Edinburgh and gene therapy momentum to target refractory cancers.[1] Trends like combo-therapy integration and AI-driven genomics will accelerate its platform, potentially expanding to solid tumors beyond initial focus areas. As a pioneer in cancer stem cell targeting, its influence could grow through partnerships or acquisitions, evolving from early-stage biotech to a key player in transformative oncology—exemplifying how targeted gene therapies redefine cancer treatment durability.[1][2]
Cellinta has raised $5.0M in total across 1 funding round.
Cellinta's investors include AbbVie Ventures, RA Capital, SV Health Investors.
Cellinta has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in January 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2020 | $5.0M Seed | AbbVie Ventures, RA Capital, SV Health Investors |